Summary
Inhibition of tyrosine kinase (TK) receptors by synthetic small molecules has become a promising new therapy option in oncology. The TK inhibitor imatinib mesylate selectively targets PDGFR-α, -β, c-kit, c-abl and arg and has proven successful in the treatment of chronic myeloid leukaemia. In recurrent glioblastoma, phase II therapy trials using imatinib mesylate have been initiated. As only a fraction of patients seems to benefit from imatinib mesylate therapy and due to potential side effects and high costs of imatinib mesylate therapy, selection of the right patients is important. The goal of our study was to assess systematically immunohistochemical expression of the major TKs targeted by imatinib mesylate in glioblastoma, as expression of these factors could be used to select patients for imatinib mesylate therapy.
In a cohort of 101 glioblastoma patients, anti-PDGFR-α, -β, c-kit, c-abl and arg protein immunohistochemistry was performed. Expression of these proteins was assessed semi-quantitatively and correlated with patient survival.
PDGFR-α and arg expression in tumor cells was widespread in 1/101 cases, respectively. Focal PDGFR-α, -β, c-kit, c-abl and arg immunolabeling was detected in 25/101, 19/101, 4/101, 7/101 and 31/101 cases, respectively. Statistical analysis did not reveal any correlation between expression of the TKs and patient survival.
We show here for the first time in a large series of glioblastomas that PDGFR-α, -β, c-kit, c-abl and arg expression is immunohistochemically detectable in a fraction of cases. The value of anti-tyrosine kinase immunolabeling as predictive factor for patient selection remains to be clarified by comparative analysis of tumor tissue of therapy-responders versus non-responders.
Similar content being viewed by others
References
SR Hubbard JH Till (2000) ArticleTitleProtein tyrosine kinase structure and function Annu Rev Biochem 69 373–398 Occurrence Handle10.1146/annurev.biochem.69.1.373 Occurrence Handle1:CAS:528:DC%2BD3cXnt1ajtb0%3D Occurrence Handle10966463
MC Heinrich DJ Griffith BJ Druker CL Wait KA Ott AJ Zigler (2000) ArticleTitleInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925–932 Occurrence Handle1:CAS:528:DC%2BD3cXltlKitLw%3D Occurrence Handle10910906
E Buchdunger CL Cioffi N Law D Stover S Ohno-Jones BJ Druker NB Lydon (2000) ArticleTitleAbl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139–145 Occurrence Handle1:CAS:528:DC%2BD3cXnt1ygur4%3D Occurrence Handle10991971
JV Melo (1996) ArticleTitleThe molecular biology of chronic myeloid leukaemia Leukemia 10 751–756 Occurrence Handle1:STN:280:BymB3MnmtV0%3D Occurrence Handle8656667
JD Rowley (1973) ArticleTitleA new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290–293 Occurrence Handle10.1038/243290a0 Occurrence Handle1:STN:280:CSuD3cnjslU%3D Occurrence Handle4126434
GQ Daley RA Etten ParticleVan D Baltimore (1990) ArticleTitleInduction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 824–830 Occurrence Handle1:CAS:528:DyaK3cXhsFaqs7c%3D Occurrence Handle2406902
BJ Druker (2002) ArticleTitleImatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy Eur J Cancer 38 IssueIDSuppl 5 S70–S76 Occurrence Handle12528776
M Miettinen M Majidi J Lasota (2002) ArticleTitlePathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review Eur J Cancer 38 IssueIDSuppl 5 S39–S51 Occurrence Handle12528772
GD Demetri (2002) ArticleTitleIdentification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) Eur J Cancer 38 IssueIDSuppl 5 S52–S59 Occurrence Handle12528773
Raymond E, Brandes. A, Van Oosterom A, Dittrich C, Fumoleau P, Coudert C, Twelves C, De Balincourt C, Lacombe D, Van den Bent M: Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. J Clin Oncol 22: 1501, 2004 (abstract)
TP Fleming A Saxena WC Clark JT Robertson EH Oldfield SA Aaronson IU Ali (1992) ArticleTitleAmplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors Cancer Res 52 4550–4553 Occurrence Handle1:CAS:528:DyaK38XlvV2ht7g%3D Occurrence Handle1322795
M Hermanson K Funa M Hartman L Claesson-Welsh CH Heldin B Westermark M Nister (1992) ArticleTitlePlatelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res 52 3213–3219 Occurrence Handle1:CAS:528:DyaK38Xkt1Cjsbw%3D Occurrence Handle1317261
P Kleihues H Ohgaki (1999) ArticleTitlePrimary and secondary glioblastomas: from concept to clinical diagnosis Neuro-Oncol 1 44–51 Occurrence Handle1:STN:280:DC%2BD3MrgtFCktg%3D%3D Occurrence Handle11550301
T Kilic JA Alberta PR Zdunek M Acar P Iannarelli T O’Reilly E Buchdunger PM Black CD Stiles (2000) ArticleTitleIntracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 60 5143–5150 Occurrence Handle1:CAS:528:DC%2BD3cXntVamur4%3D Occurrence Handle11016641
M Dowsett J Bartlett IO Ellis J Salter M Hills E Mallon AD Watters T Cooke C Paish PM Wencyk SE Pinder (2003) ArticleTitleCorrelation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 418–423 Occurrence Handle10.1002/path.1313 Occurrence Handle1:CAS:528:DC%2BD3sXlt1Sgtrc%3D Occurrence Handle12635131
P Birner M Piribauer I Fischer B Gatterbauer C Marosi PF Ambros IM Ambros M Bredel G Oberhuber K Rossler H Budka AL Harris JA Hainfellner (2003) ArticleTitleVascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes Brain Pathol 13 133–43 Occurrence Handle1:CAS:528:DC%2BD3sXjsF2gurw%3D Occurrence Handle12744467
M Hermanson K Funa J Koopmann D Maintz A Waha B Westermark CH Heldin OD Wiestler DN Louis A von-Deimling M Nister (1996) ArticleTitleAssociation of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas Cancer Res 56 164–171 Occurrence Handle1:CAS:528:DyaK28Xit1Cgsg%3D%3D Occurrence Handle8548759
A Das WL Tan J Teo DR Smith (2002) ArticleTitleGlioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway J Neuro-Oncol 60 117–25 Occurrence Handle10.1023/A:1020622415786
KH Plate G Breier CL Farrell W Risau (1992) ArticleTitlePlatelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas Lab Invest 67 529–534 Occurrence Handle1:STN:280:ByyD28%2FptVQ%3D Occurrence Handle1434531
M Stanulla K Welte MR Hadam T Pietsch (1995) ArticleTitleCoexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines Acta neuropathol 89 158–165 Occurrence Handle1:CAS:528:DyaK2MXltlansbk%3D Occurrence Handle7537428
M Tada AC Diserens I Desbaillets N de-Tribolet (1994) ArticleTitleAnalysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction J Neurosurg 80 1063–1073 Occurrence Handle1:CAS:528:DyaK2cXkvVSksLk%3D Occurrence Handle7514661
WE Berdel S De-Vos J Maurer D Oberberg Z Von-Marschall JK Schroeder J Li WD Ludwig ED Kreuser E Thiel F Herrmann (1992) ArticleTitleRecombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene Cancer Res 52 3498–3502 Occurrence Handle1:CAS:528:DyaK38Xks1elu78%3D Occurrence Handle1375870
N Blin R Muller-Brechlin C Carstens E Meese KD Zang (1987) ArticleTitleEnhanced expression of four cellular oncogenes in a human glioblastoma cell line Cancer Genet Cytogenet 25 285–292 Occurrence Handle10.1016/0165-4608(87)90189-0 Occurrence Handle1:CAS:528:DyaL2sXkslGgtr0%3D Occurrence Handle3828971
RA Etten ParticleVan (1999) ArticleTitleCycling, stressed-out and nervous: cellular functions of c-Abl Trends Cell Biol 9 179–186 Occurrence Handle10322452
AJ Koleske AM Gifford ML Scott M Nee RT Bronson KA Miczek D Baltimore (1998) ArticleTitleEssential roles for the Abl and Arg tyrosine kinases in neurulation Neuron 21 1259–1272 Occurrence Handle10.1016/S0896-6273(00)80646-7 Occurrence Handle1:CAS:528:DyaK1MXntVOrtg%3D%3D Occurrence Handle9883720
F Medeiros CL Corless A Duensing JL Hornick AM Oliveira MC Heinrich JA Fletcher CD Fletcher (2004) ArticleTitleKIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications Am J Surg Pathol 28 889–894 Occurrence Handle15223958
E Buchdunger T O’Reilly J Wood (2002) ArticleTitlePharmacology of imatinib (STI571) Eur J Cancer 38 IssueIDSuppl 5 S28–S36 Occurrence Handle12528770
Borg (2004) ArticleTitleNovel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects J Clin Invest 114 379–388 Occurrence Handle10.1172/JCI200421102 Occurrence Handle1:CAS:528:DC%2BD2cXmtlynsrc%3D Occurrence Handle15286804
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haberler, C., Gelpi, E., Marosi, C. et al. Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy. J Neurooncol 76, 105–109 (2006). https://doi.org/10.1007/s11060-005-4570-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-4570-9